Equillium, Inc.

Phase A — Understand the business

Lens 1 · Company Overview

Equillium, Inc. (Delaware, incorporated 2017; HQ 2223 Avenida de la Playa, La Jolla CA; ticker EQ on Nasdaq Capital Market) is a clinical-/preclinical-stage biotech developing therapies for severe autoimmune and inflammatory disorders. It manages the business as one operating segment. It has no product revenue and (per the 10-K) "does not expect to generate any revenues from product sales … which is unlikely to happen within the next 12 months, if ever".

What it actually is today: a re-tooled pipeline play. The stated primary goal is to "advance EQ504, a novel AhR modulator, into and through clinical development".

The pipeline (both preclinical):

• EQ504 — preclinical-stage, selective aryl-hydrocarbon-receptor (AhR) modulator, gut-restricted/orally delivered. Lead indication ulcerative colitis (and pouchitis / other GI), with indication-expansion to inflammatory lung disease. Mechanism: a multi-modal, non-immunosuppressive MoA that induces anti-inflammatory cytokines (IL-10, IL-22), reduces proinflammatory signals, and improves intestinal barrier function/repair.
• EQ302 — preclinical-stage, "first-in-class, selective, bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery," for celiac and other GI indications (IBD, EoE). Earlier-stage than EQ504; toxicology/IND-enabling work ongoing.

History (what was abandoned): itolizumab (anti-CD6 mAb, aGVHD/lupus — partnered then de-partnered with Biocon/Ono); the EQ101/EQ102 multi-cytokine peptides (IL-2/9/15) for alopecia areata and celiac — EQ101's Phase 2 alopecia data were underwhelming, prompting the swap to oral EQ302.

Customers / suppliers / competitors: No customers (no product). Inputs = a 14-person headcount plus third-party CMOs/CROs for manufacturing and trials — heavy outsourcing dependency. customers.csv is empty (no commercial relationships). Competitors covered in Lens 3.

Lens 2 · Supply Chain (→ CDMO / manufacturing, per +clinical overlay)

A preclinical biotech has no commercial supply chain; the relevant "supply chain" is the discovery → IND → clinic development chain and who controls each node:

• Upstream IP / molecules: EQ504 and EQ302 came in via the Ariagen, Inc. acquisition (Oct 2024). Equillium holds exclusive worldwide rights to both. Note: Ariagen was majority-owned by Decheng Capital, Equillium's largest investor — a related-party origin (see Lens 9/10).
• Manufacturing: outsourced to third-party CMOs/CDMOs — Equillium does not own manufacturing. This is single-point execution risk for a 14-person company.
• Clinical execution: CROs; the EQ504 Phase 1 PoM study may run outside the U.S. (possibly without a U.S. IND), to move faster.
• Formulation partner (historical): Vivtex (GI-targeted oral formulation research agreement for the bi-specific peptide).
• Chokepoint: the binding constraints are (1) CDMO drug-substance/product supply for tox + Phase 1, and (2) regulatory clearance to dose. Both are outside management's direct control. supply-chain.md / bottlenecks.md for biopharma are not yet compiled.

Lens 3 · Competitive Advantages (moats) (→ IP / data / platform moat, per +clinical overlay)

For a preclinical biotech the moat is IP + mechanism differentiation + speed, not scale/brand:

• IP estate (EQ504): four AhR-modulator patent families. The first family includes issued U.S., Korean, and Hong Kong patents; U.S./Korean expire 2037, Hong Kong 2039; further families (indole chemical class) in prosecution incl. PCT. A ~2037+ composition-of-matter runway is genuine moat if the asset works.
• Mechanistic differentiation: EQ504 is positioned as a selective AhR modulator (vs. blunt agonists) with gut-restricted / minimal-systemic-exposure delivery and a non-immunosuppressive profile — a real differentiator vs. systemic immunosuppressants (JAK inhibitors, S1P modulators, anti-integrins, anti-TL1A) that dominate UC. The competitive claim is "local action, fewer systemic safety liabilities".
• Bargaining power: essentially none today — pre-data, no commercial leverage, dependent on capital markets and CMOs. Moat is entirely prospective and contingent on the Phase 1/2 data validating the mechanism.
• The honest read: the moat is "a differentiated preclinical mechanism with a patent runway." That is a thesis, not a moat yet. Until human data exist, the durable competitive advantage is unproven.

Lens 4 · Segments

One operating segment; no product revenue → no meaningful segment economics. The only "segment" lens that matters is spend allocation:

• FY2025 R&D $12.843M (down from $37.428M FY2024 — a deliberate, severe cut as itolizumab wound down).
• FY2025 G&A $10.791M (down modestly from $11.936M).
• The R&D collapse is the signature of the pivot: they stopped funding a failed Phase 3 and redirected a much smaller envelope toward IND-enabling work on EQ504/EQ302. R&D will re-inflate as EQ504 enters the clinic.

---

Phase B — Measure performance (clinical overlay: pipeline / catalysts / rNPV replace earnings)

Lens 5 · Pipeline by phase (replaces "Earnings Result" — +clinical overlay)

The asset table is the company:

Sources:;.

The single most important fact in this dossier: both lead assets are preclinical. There is zero human efficacy data on EQ504. The mid-2026 Phase 1 is a proof-of-mechanism (biomarker/PD) study, not a Phase 2 efficacy trial — so even a "good" readout in early 2027 is a mechanistic signal, not proof the drug treats UC.

Latest financials (the books behind the pivot):

• Cash & equivalents: $61.322M at Mar 31 2026 (up from $30.277M at Dec 31 2025; $18.085M at Dec 31 2024).
• FY2025 net loss $(22.398)M; FY2025 loss from operations $(23.634)M on $0 revenue.
• Q1 2026 net loss $(5.311)M ($(0.06)/sh); operating cash burn $(4.301)M → ~$17M annualized.
• Accumulated deficit $(216.205)M; total stockholders' equity $28.597M (Dec 31 2025), boosted post-Q1 by the March raise.
• Runway: "into 2029" — reaffirmed in the Q1 10-Q as of Mar 31 2026. My check: $61.3M ÷ ~$17M ≈ 3.6 yrs → into ~2029–2030, so management's claim is credible-to-conservative.

Lens 7 · Catalyst calendar + mechanism comps (replaces "Comps" — +clinical overlay)

Catalyst calendar (what de-risks or kills the thesis, and when):

Mechanism comps (by target, not by P/E — there are no earnings):

• AhR in UC / gut inflammation: Adial/Azora (AT177) — colon-targeted AhR agonist, acquired by Adial Jun 2026; the most direct mechanistic competitor. Academic AhR-ligand programs (NPD-0414 series, etc.) remain preclinical. EQ504's differentiation claim = selective modulator + gut-restriction.
• Broader UC competitive set (the real bar EQ504 must beat): Abivax obefazimod (oral, Ph3 readouts — different MoA, miR-124), plus approved/late JAK inhibitors (upadacitinib), S1P modulators (etrasimod/ozanimod), anti-TL1A (Roche/RVT-3101, Merck/MK-7240), IL-23s. UC is a crowded, well-capitalized field.
• EQ302 / celiac comps: Takeda is the gorilla — TAK-101 (tolerizing nanoparticle), TAK-227/ZED-1227 (TG2 inhibitor), zamaglutenase/TAK-062 (glutenase); plus Anokion KAN-101, Topas, First Tracks ANB033 (anti-CD122), latiglutenase. Celiac is more crowded and later-stage than EQ504's UC niche.
• Valuation comps: n/a. No EV/Sales, EV/EBIT, P/E, or ROE peer table is meaningful for a $0-revenue preclinical name. The only valuation read is "EV vs. cash vs. probability-weighted asset value" — see Lens 11.

Lens 8 · Stock-Price Catalysts (the tape)

What has moved EQ >5% over the relevant window — almost entirely binary clinical/financing events, the classic single-asset profile:

• 2020: itolizumab aGVHD interim data (up moves).
• 2023–2024: EQUATOR Phase 3 primary-endpoint miss + FDA Breakthrough decline → severe de-rating; stock fell toward delisting territory.
• Dec 2024: Nasdaq minimum-bid-price non-compliance notice ($1.00 rule) — stock sub-$0.35.
• May 2025: EQ504 program announcement + up-to-$50M financing → the pivot narrative begins.
• Aug 2025: ~$30M private placement at $0.57; stock regained Nasdaq compliance Aug 29 2025 (≥$1.00 for 10 consecutive days) — no reverse split needed.
• Mar 2026: ~$35M placement led by RA Capital at $1.854/sh (1.18M shares + 17.7M pre-funded warrants).
• 2026 sell-side initiations: Raymond James "Strong Buy," PT $6.00; Oppenheimer "Outperform," PT $7.00 — both well above the ~$3 print.
• Result: $0.32 (Jun 30 2025) → ~$3.05 (Jun 18 2026), a ~9–10x move; 52-week range $0.27–$3.45. The pattern is unambiguous: this name reacts to pivot narrative, tier-1 financing, and (soon) the Phase 1 readout — not fundamentals (there are none yet).

---

Phase C — Judge people & books (+ Science & exclusivity, per +clinical overlay)

Lens 9 · Management

• Bruce D. Steel (Co-Founder, President & CEO; also CFO from 2025), CFA, MBA. Career financier/operator: previously Founder & MD of BioMed Ventures (the strategic investment arm of BioMed Realty), where he directed investments in 30+ biotechs including Receptos, AnaptysBio, Auspex, eFFECTOR, Compass, NeoTract — several of which became major M&A/clinical successes. Skin in the game: 6.1% direct ownership ($3.97M). Archetype: dealmaker/capital-allocator founder, not a bench scientist — which fits a company whose recent value-creation has been transactional (Ariagen in, itolizumab out, RA Capital in).
• Daniel Bradbury (Executive Chairman, Co-Founder). Ex-President & CEO of Amylin Pharmaceuticals (1994–2012), which launched three first-in-class medicines and was acquired by Bristol-Myers Squibb for ~$5.3B in 2012; current/former boards incl. Intercept, Castle Biosciences, Biocon, Vivani. A genuinely credible biotech-builder pedigree — the single strongest "people" data point.
• Capital-allocation history — mixed-to-poor on the old company, decisive on the pivot. The bear read: they burned $216M and 8 years on itolizumab that failed Phase 3 — value destruction. The bull read: once it failed, management cut R&D ~66%, did not do a reverse split, regained Nasdaq compliance, acquired a differentiated new platform cheaply (Ariagen), and pulled in RA Capital — a tidy survival-and-reload. ROE is ~-94% (negative, as expected pre-revenue).
• Red flags: (1) Related-party acquisition — Ariagen (source of both current assets) was majority-owned by Decheng Capital, Equillium's largest investor; the deal carries up to $55M in success-based milestones to Ariagen holders. An insider selling the company its entire new pipeline warrants scrutiny of deal terms (independent-committee review, valuation fairness). (2) CEO holding both CEO and CFO titles (from 2025) reduces financial-control separation at a micro-cap. Neither is disqualifying; both are governance items to watch.

Lens 10 · Forensic Red Flags

• Auditor change (yellow flag). The FY2025 financials were audited by Crowe LLP (Costa Mesa CA; Auditor Firm ID 173), while the FY2024/2023 comparatives carry the prior KPMG LLP opinion (San Diego; auditor since 2018, signed Mar 27 2025). A switch from a Big Four (KPMG) to a smaller national firm (Crowe) around a strategic reset is worth noting, though common for shrinking micro-caps managing audit cost.
• Going-concern history. The KPMG opinion on FY2024/2023 carried an explicit going-concern / substantial-doubt paragraph. However, the post-March-2026 liquidity position (cash funding ops "into 2029") materially relieves near-term going-concern pressure — the Q1 10-Q asserts cash is sufficient "for at least the next 12 months." This is a case where the forensic flag is real but partly cured by the raise — verify the FY2025 (Crowe) opinion language at next refresh for whether substantial doubt was removed.
• Revenue recognition: N/A — $0 revenue FY2025; the prior $41.1M (FY2024) was Ono collaboration/asset-purchase income, now terminated. Clean by virtue of having nothing to recognize.
• Cash vs. earnings divergence: Net loss $(22.4)M vs. operating cash burn $(22.7)M FY2025 — tightly aligned, no accrual games; SBC modest ($2.3M FY2025, $0.93M Q1 2026).
• Dilution (the real shareholder risk, not fraud): shares 35.6M → 61.5M (Dec 2025) → 63.2M (Mar 2026), plus 17.7M pre-funded warrants outstanding and a live ATM facility (Jefferies, ~$22M; one source cites a $75M facility). Weighted-avg diluted shares were 96.3M in Q1 2026 (pre-funded warrants counted). Future clinical funding will dilute further.
• Balance sheet: clean and simple — no debt, minimal leases, $61.3M cash, $0.76M payables.

Regulatory findings (required sub-section).

• SEC Litigation Releases: None for Equillium, Inc. (EDGAR EFTS LR search, 2021-06-20 → 2026-06-20).
• SEC AAERs: None in the same window.
• Item 3 (Legal Proceedings), FY2025 10-K: "None." — the company discloses no material litigation.
• Non-SEC enforcement (FTC/DOJ/FDA/CFPB) web check: no material enforcement actions surfaced; the only FDA "negative" is the Breakthrough-Therapy denial for itolizumab (a regulatory designation decision, not an enforcement action).
• Net: No material regulatory or legal findings — verified via SEC EDGAR EFTS (LR, AAER), 10-K Item 3 ("None"), and web search as of 2026-06-20.

Science & exclusivity (per +clinical overlay):

• Mechanism validation: AhR modulation for gut inflammation has plausible, published preclinical rationale (DSS-colitis models; IL-10/IL-22 induction; barrier repair) but no approved AhR drug exists for IBD — mechanism is unvalidated in humans. EQ302's IL-15/IL-21 thesis in celiac is biologically well-supported (IL-15 is a recognized celiac driver) but, again, preclinical.
• IP/exclusivity: EQ504 composition-of-matter to 2037 (US/KR), 2039 (HK) + prosecuting families — a strong runway if it works.
• Reimbursement/payer path: irrelevant near-term (years from approval).

---

Phase D — Project & stress-test

Lens 11 · rNPV + runway-to-catalyst (replaces "Forward Projection" — +clinical overlay)

No EPS model is appropriate (zero revenue, no clinical data, no guidance.csv). The right frame is runway-to-catalyst + a coarse rNPV sketch, all ``.

Runway-to-catalyst (the question that actually matters): Does cash reach the next value-inflection? Yes, comfortably. $61.3M cash (Mar 2026) at ~$17M/yr burn = ~3.6 yrs → funds through both the mid-2026 Phase 1 start and the early-2027 PoM data, with multi-year buffer; the Aug-2025 second closing ($20M) and ATM provide additional optional capital. This is the single most de-risking fact for a holder — runway is not the near-term risk; data is.

Coarse rNPV sketch (EQ504, illustrative — every input labeled, do not trust to a dollar):

• UC is a multi-billion-dollar market; a differentiated, safe oral UC drug could plausibly reach $1–2B peak sales if approved.
• Preclinical-to-approval PoS for a novel-mechanism GI small molecule ≈ ~8–12%.
• rNPV ≈ peak-sales × PoS × margin × discount-to-present. Even a back-of-envelope $1.5B peak × 10% PoS × ~3–4x sales-to-NPV multiple, discounted ~10–12% over ~8–10 yrs lands the risk-adjusted EQ504 value in a band that is not wildly out of line with today's ~$130–185M EV — i.e., the market is paying roughly fair value for a 1-in-10 shot, before any human data. EQ302 is upside optionality on top.
• Interpretation: the stock is priced as a call option struck on the Phase 1 PoM readout. The asymmetry (small cap, big TAM, binary catalyst) is the entire bull case; the ~10% base-rate PoS is the entire bear case.

Brier forecast (the binary that matters — log per overlay, NOT an EPS line):

EQ — EQ504 Phase 1 proof-of-mechanism study INITIATED by 2026-12-31, p ≈ 0.80 (management-guided mid-2026; well-funded; but micro-caps slip). Not logged via forecast.ts — this is the --watchlist loop (no forecast create per skill rules); recorded here for /thesis to lift. Secondary: EQ — EQ504 Phase 1 PoM reports a positive PD/biomarker signal by 2027-06-30, p ≈ 0.45.

Lens 12 · Bull vs Bear

Bull case. Equillium is a recapitalized, de-risked-on-runway shot at a differentiated UC mechanism with a clean balance sheet and unusually strong sponsorship for a micro-cap. The setup: (1) RA Capital-led March raise + Decheng backing = tier-1 healthcare crossover validation; (2) >3yr runway funds the company through its own value-inflection without forced dilution; (3) EQ504's gut-restricted, non-immunosuppressive profile is genuinely attractive in a UC market where systemic safety (JAK black-box, infection risk) is the key liability; (4) patent runway to 2037+; (5) credible management (Bradbury's Amylin→BMS exit, Steel's BioMed Ventures hit-list); (6) sell-side initiating bullish (RJ $6, Oppenheimer $7 vs. ~$3 spot). If the mid-2026 Phase 1 throws a clean PD signal, this re-rates hard off a ~$190M base — classic small-cap binary asymmetry. EQ302 (celiac) is a free option on top.

Bear case (2–3 things that permanently impair). (1) Both lead assets are preclinical — there is ZERO human data on EQ504. A proof-of-mechanism study is the first gate; even success is mechanistic, not efficacy. Preclinical-stage failure is the base case (~88–92% of such assets never reach approval). (2) Single-asset concentration on an unvalidated mechanism — no approved AhR drug exists for IBD; if the mechanism doesn't translate to humans, the equity is worth ~cash-minus-burn, and EQ302 (earlier, crowded celiac field) is unlikely to carry the company alone. (3) Serial value destruction is the track record — $216M and 8 years already incinerated on itolizumab; the same team is now asking the market to fund attempt #2. (4) Structural dilution — pre-funded warrants + live ATM + future clinical raises mean today's ~63M shares is not the denominator that matters at approval.

Pre-mortem (it's late 2027, the thesis broke — what happened?). Most likely: the EQ504 Phase 1 PoM readout (~early 2027) was ambiguous or negative — no clean biomarker/PD signal, or a tolerability issue — and the stock round-trips back toward cash value (sub-$1). Alternatively: the study slipped (CMO/regulatory delay), the second-closing milestone wasn't hit, the narrative went cold, and dilution via the ATM ground the price down. Tail: a safety signal in the AhR class (a competitor's agonist) tarnishes the mechanism.

Are multiples too high? There are no multiples (no revenue). On an rNPV/option basis, the stock is ~fairly priced for a ~10% shot — not obviously cheap, not obviously expensive. The market has already paid for the pivot (9–10x off the lows). You are no longer buying the "left-for-dead" trough; you're buying a pre-data option at a price that bakes in meaningful EQ504 optimism.

Contrarian view (what the market may be refusing to see): Bulls anchoring on RJ/Oppenheimer's $6–7 targets may be under-pricing how binary and early this is — a proof-of-mechanism study is not a Phase 2; the gap between "PD signal" and "treats UC" is enormous and years away. Conversely, bears dismissing it as "another failed-biotech zombie" may be under-pricing the runway + sponsorship — RA Capital and a 3.6-yr cash cushion mean this won't die for lack of money before it gets its shot, which is rarer than it sounds at this market cap.

Lens 13 · Devil's Advocate (short-seller)

Dismantling the bull case:

• The entire equity rests on a molecule no human has taken. "Differentiated mechanism" is a slide, not data. The honest PoS is ~1-in-10. At ~$190M cap you're paying a premium-to-cash for a lottery ticket whose first scratch is ~9 months out and is only a mechanism check.
• Revenue concentration is total and theoretical — 100% of future value is EQ504 (EQ302 is even earlier). One bad readout and the moat, the patents, and the TAM are all worthless.
• The moat is weaker than bulls think: AhR-for-gut is an active competitive area (Azora/Adial's AT177, academic programs); UC itself is a knife-fight (JAKs, S1Ps, anti-TL1A, IL-23s, obefazimod). "Gut-restricted AhR" must out-compete a dozen funded mechanisms — and it's the last to the clinic among them.
• Most dangerous competitor bulls underestimate: in UC, the anti-TL1A class (Roche/RVT-3101, Merck/MK-7240) and oral S1P/obefazimod — these are years ahead with efficacy data and will define the bar EQ504 must clear long before EQ504 has Phase 2 data.
• Capital-allocation / governance red flags: the Ariagen related-party acquisition (insider Decheng selling Equillium its whole pipeline, $55M milestones), the CEO=CFO dual role, the KPMG→Crowe auditor switch, and the $216M already destroyed are exactly the pattern a skeptic flags as "promotional reload."
• Assumptions that must hold for ~$3: (a) Phase 1 starts on time, (b) PD data are clean, (c) the mechanism translates, (d) they fund Phase 2 without crushing dilution. Miss any one and fair value is ~cash ($61M ≈ <$1/sh on basic shares, less on fully-diluted).
• If growth/data disappoints 20–30% — irrelevant framing here; this is binary, not a growth de-rate. A failed/ambiguous PoM doesn't trim 25%, it likely halves-or-worse the equity toward cash.
• Single scenario that permanently impairs: the EQ504 PoM study reads out negative/ambiguous on PD + safety in early 2027 — plausible (>50% odds of not a clean win), and it takes the differentiated-mechanism thesis with it.

Lens 14 · Management Questions (ordered by information value)

1. EQ504 Phase 1 — what specific PD/biomarker endpoints define "proof of mechanism," and what threshold would you call a clean positive vs. ambiguous?
2. Is the mid-2026 Phase 1 initiation on track, and is it US-IND or ex-US — what's the regulatory path and timeline to first-patient-dosed?
3. What is the gating data package and decision point for advancing EQ504 from Phase 1 PoM into a Phase 2 efficacy study in UC?
4. Walk through the Ariagen related-party transaction: who sat on the independent committee, how was the $55M-milestone consideration valued, and how was Decheng's conflict managed?
5. What is the EQ302 IND-enabling timeline, and at what point does EQ302 compete with EQ504 for the same capital?
6. Given the live ATM and pre-funded warrants, what is your dilution philosophy — under what conditions do you tap the ATM before Phase 1 data?
7. The Aug-2025 second closing (~$20M) is milestone-gated to clinical-study initiation + stock price — what exactly triggers it, and do you expect it to fund?
8. How do you position EQ504 against the anti-TL1A and oral S1P / obefazimod wave that will have UC efficacy data years ahead of you?
9. What is the differentiation vs. Azora/Adial's AT177 (colon-targeted AhR agonist) — modulator vs. agonist, and why does that matter clinically?
10. Why the KPMG → Crowe auditor change, and were there any disagreements on accounting or scope?
11. CEO and CFO are the same person — what's the plan and timeline to separate financial oversight as you re-enter the clinic?
12. What CMO/CDMO dependencies sit on the EQ504 critical path, and what is the second-source/risk-mitigation plan?
13. What did you learn from the itolizumab Phase 3 failure that changes how you design and de-risk EQ504's clinical program?
14. What is the realistic capital required to reach an EQ504 Phase 2 efficacy readout, and where does it come from?
15. Under what circumstances would you pursue a partnership/licensing deal for EQ504 vs. going it alone, and at what stage?

---